Steven P. Coen (Officer) plans to sell ~$36K of Ginkgo Bioworks Holdings
Planned, from payLoading…
DNA · NYSE · Biological Products, (No Diagnostic Substances)
Biological Products, (No Diagnostic Substances) company based in Boston, Ma.
In the last 90 days, no insider of Ginkgo Bioworks Holdings reported an open-market purchase and 0 open-market sales. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 6, 2026
$12.41
Last 12 months
Not enough history
Market value
Not available
Bets against the stock: 7.17M shares sold short, +4.4% vs the previous count, 7.2 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$20.2M
−48.5% vs the same quarter a year earlier
Free cash flow, last 12 months
−$175M
This quarter −$46.9M, a year earlier −$40.3M
Net debt
—
Debt —, cash $84.5M, at Jun 30, 2026
Backlog
$113M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 5, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.